Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

90 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Automated radiosynthesis of [89Zr]Zr-DFOSq-Durvalumab for imaging of PD-L1 expressing tumours in vivo.
Wichmann CW, Poniger S, Guo N, Roselt P, Rudd SE, Donnelly PS, Blyth B, Van Zuylekom J, Rigopoulos A, Burvenich IJG, Morandeau L, Mohamed S, Nowak AK, Hegi-Johnson F, MacManus M, Scott AM. Wichmann CW, et al. Among authors: blyth b. Nucl Med Biol. 2023 May-Jun;120-121:108351. doi: 10.1016/j.nucmedbio.2023.108351. Epub 2023 May 16. Nucl Med Biol. 2023. PMID: 37224789 Free article.
PD-L1 Positron Emission Tomography Imaging in Patients With Non-Small Cell Lung Cancer: Preliminary Results of the ImmunoPET Phase 0 Study.
Hegi-Johnson F, Rudd SE, Wichmann CW, Akhurst T, Roselt P, Sursock S, Trinh J, John T, Devereux L, Donnelly PS, Hicks RJ, Scott AM, Steinfort D, Fox S, Blyth B, Parakh S, Hanna GG, Callahan J, Burbury K, MacManus M. Hegi-Johnson F, et al. Among authors: blyth b. Int J Radiat Oncol Biol Phys. 2023 Nov 1;117(3):675-682. doi: 10.1016/j.ijrobp.2023.05.019. Epub 2023 Jul 3. Int J Radiat Oncol Biol Phys. 2023. PMID: 37406824 No abstract available.
An immunomodulating peptide to counteract solar radiation-induced immunosuppression and DNA damage.
Agrez M, Rybchyn MS, De Silva WGM, Mason RS, Chandler C, Piva TJ, Thurecht K, Fletcher N, Liu F, Subramaniam G, Howard CB, Blyth B, Parker S, Turner D, Rzepecka J, Knox G, Nika A, Hall A, Gooding H, Gallagher L. Agrez M, et al. Among authors: blyth b. Sci Rep. 2023 Jul 20;13(1):11702. doi: 10.1038/s41598-023-38890-4. Sci Rep. 2023. PMID: 37474630 Free PMC article.
An immunomodulating peptide with potential to suppress tumour growth and autoimmunity.
Agrez M, Chandler C, Thurecht KJ, Fletcher NL, Liu F, Subramaniam G, Howard CB, Blyth B, Parker S, Turner D, Rzepecka J, Knox G, Nika A, Hall AM, Gooding H, Gallagher L. Agrez M, et al. Among authors: blyth b. Sci Rep. 2023 Nov 13;13(1):19741. doi: 10.1038/s41598-023-47229-y. Sci Rep. 2023. PMID: 37957274 Free PMC article.
ImmunoPET: IMaging of cancer imMUNOtherapy targets with positron Emission Tomography: a phase 0/1 study characterising PD-L1 with 89Zr-durvalumab (MEDI4736) PET/CT in stage III NSCLC patients receiving chemoradiation study protocol.
Hegi-Johnson F, Rudd SE, Wichmann C, Akhurst T, Roselt P, Trinh J, John T, Devereux L, Donnelly PS, Hicks R, Scott AM, Steinfort D, Fox S, Blyth B, Parakh S, Hanna GG, Callahan J, Burbury K, MacManus M. Hegi-Johnson F, et al. Among authors: blyth b. BMJ Open. 2022 Nov 18;12(11):e056708. doi: 10.1136/bmjopen-2021-056708. BMJ Open. 2022. PMID: 36400733 Free PMC article. Clinical Trial.
90 results